Table 4.
Studies evaluating the effects of anti‐TNFα treatment on endothelial function measured by FBF in patients with CID
| Reference | CID | Study design | Outcome measures and results |
|---|---|---|---|
| 65 | 10 antibody associated systemic vasculitis | Intravenous infusion of infliximab alone or as additional therapy in AASV patients. Measurements taken at baseline and 12 weeks and compared to 21 healthy controls. | 1. No change in FBF compared to control group. |
| 66 | 10 RA | Intravascular administration of infliximab at 200 μg min–1 for 60 min. FBF response measured every 30 min and compared to response to saline infusion. | 1. Improved FBF response to ACh (P = .004) but not to SNP. |
| 67 | 30 RA | 30 RA patients treated with either etanercept/adalimumab and 21 with MTX. Follow‐up at 2 and 4 months. | 1. No improvement in FBF response. |
| 68 | 8 RA | Etanercept for 2 weeks at 2 × 25 mg doses. No controls. | 1. No change in FBF response. |
| 23 | 15 RA | RA subjects received infliximab infusions at week 0, 2 and 6 at 3 mg kg–1. No controls. | 1. Significant improvement in FBF response post‐infliximab (P < .05). |
| 69 | 3 primary systemic vasculitis | 10 infusions of infliximab at 5 mg kg–1. Measurements taken at day 0,1,2,5 and 14. No controls. | 1. FBF to ACh improved significantly within 24 hours of inflimab infusion, but was not maintained at day 14. No change in SNP dilation. |
| 62 | 23 RA | Treated with either infliximab, etanercept or adalimumab. Assessments at baseline, 2 weeks and 3 months. No controls. | 1. ACh mediated dilation improved at week 2 vs. baseline only (P = .001) but no change in SNP dilation. |
| 70 | 12 CD and 12 UC | Cross‐sectional study comparing the response to infliximab infusion for 60 min. IBD groups compared with each other and healthy controls. |
1. Infliximab improved ACh vasodilation in CD vs. controls (P = .005), but not in UC. 2. No change in SNP vasodilation in either CD or UC. |
CID: chronic inflammatory disease; RA: rheumatoid arthritis; PsA: psoriatic arthritis; AS: ankylosing spondilitis; IBD: inflammatory bowel disease; CD: Crohn's disease; UC: ulcerative colitis; anti‐TNF: anti‐tumour necrosis factor; FBF: forearm blood flow; ACh: acetylcholine (endothelium dependant dilation); SNP: sodium nitroprusside (independent dilation); GTN: glyceryl trinitrate; MTX: methotrexate.